These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

454 related articles for article (PubMed ID: 31649109)

  • 21. Oncogenic KRAS Reduces Expression of FGF21 in Acinar Cells to Promote Pancreatic Tumorigenesis in Mice on a High-Fat Diet.
    Luo Y; Yang Y; Liu M; Wang D; Wang F; Bi Y; Ji J; Li S; Liu Y; Chen R; Huang H; Wang X; Swidnicka-Siergiejko AK; Janowitz T; Beyaz S; Wang G; Xu S; Bialkowska AB; Luo CK; Pin CL; Liang G; Lu X; Wu M; Shroyer KR; Wolff RA; Plunkett W; Ji B; Li Z; Li E; Li X; Yang VW; Logsdon CD; Abbruzzese JL; Lu W
    Gastroenterology; 2019 Nov; 157(5):1413-1428.e11. PubMed ID: 31352001
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Distinct clinical outcomes and biological features of specific KRAS mutants in human pancreatic cancer.
    McIntyre CA; Grimont A; Park J; Meng Y; Sisso WJ; Seier K; Jang GH; Walch H; Aveson VG; Falvo DJ; Fall WB; Chan CW; Wenger A; Ecker BL; Pulvirenti A; Gelfer R; Zafra MP; Schultz N; Park W; O'Reilly EM; Houlihan SL; Alonso A; Hissong E; Church GM; Mason CE; Siolas D; Notta F; Gonen M; Dow LE; Jarnagin WR; Chandwani R
    Cancer Cell; 2024 Sep; 42(9):1614-1629.e5. PubMed ID: 39214094
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Precise and efficient silencing of mutant Kras
    Jiang W; Li H; Liu X; Zhang J; Zhang W; Li T; Liu L; Yu X
    Theranostics; 2020; 10(25):11507-11519. PubMed ID: 33052229
    [No Abstract]   [Full Text] [Related]  

  • 24. PI3K regulation of RAC1 is required for KRAS-induced pancreatic tumorigenesis in mice.
    Wu CY; Carpenter ES; Takeuchi KK; Halbrook CJ; Peverley LV; Bien H; Hall JC; DelGiorno KE; Pal D; Song Y; Shi C; Lin RZ; Crawford HC
    Gastroenterology; 2014 Dec; 147(6):1405-16.e7. PubMed ID: 25311989
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Loss of heterozygosity for Kras
    Ma Y; Li Y; Ling S; Li X; Kong B; Hu M; Huang P
    Biochem Biophys Res Commun; 2020 Jun; 526(4):880-888. PubMed ID: 32279996
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Kras mutation rate precisely orchestrates ductal derived pancreatic intraepithelial neoplasia and pancreatic cancer.
    Singh K; Pruski M; Bland R; Younes M; Guha S; Thosani N; Maitra A; Cash BD; McAllister F; Logsdon CD; Chang JT; Bailey-Lundberg JM
    Lab Invest; 2021 Feb; 101(2):177-192. PubMed ID: 33009500
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Phellodendrine chloride suppresses proliferation of KRAS mutated pancreatic cancer cells through inhibition of nutrients uptake via macropinocytosis.
    Thu PM; Zheng ZG; Zhou YP; Wang YY; Zhang X; Jing D; Cheng HM; Li J; Li P; Xu X
    Eur J Pharmacol; 2019 May; 850():23-34. PubMed ID: 30716311
    [TBL] [Abstract][Full Text] [Related]  

  • 28. mTORC1 and mTORC2 Converge on the Arp2/3 Complex to Promote Kras
    Zhao Y; Schoeps B; Yao D; Zhang Z; Schuck K; Tissen V; Jäger C; Schlitter AM; van der Kammen R; Ludwig C; D'Haese JG; Raulefs S; Maeritz N; Shen S; Zou X; Krüger A; Kleeff J; Michalski CW; Friess H; Innocenti M; Kong B
    Gastroenterology; 2021 Apr; 160(5):1755-1770.e17. PubMed ID: 33388318
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The KRAS mutational spectrum and its clinical implications in pancreatic cancer.
    Perelli L; Genovese G; Draetta GF
    Cancer Cell; 2024 Sep; 42(9):1494-1496. PubMed ID: 39214093
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CHK1 protects oncogenic KRAS-expressing cells from DNA damage and is a target for pancreatic cancer treatment.
    Klomp JE; Lee YS; Goodwin CM; Papke B; Klomp JA; Waters AM; Stalnecker CA; DeLiberty JM; Drizyte-Miller K; Yang R; Diehl JN; Yin HH; Pierobon M; Baldelli E; Ryan MB; Li S; Peterson J; Smith AR; Neal JT; McCormick AK; Kuo CJ; Counter CM; Petricoin EF; Cox AD; Bryant KL; Der CJ
    Cell Rep; 2021 Nov; 37(9):110060. PubMed ID: 34852220
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Nicotine promotes initiation and progression of KRAS-induced pancreatic cancer via Gata6-dependent dedifferentiation of acinar cells in mice.
    Hermann PC; Sancho P; Cañamero M; Martinelli P; Madriles F; Michl P; Gress T; de Pascual R; Gandia L; Guerra C; Barbacid M; Wagner M; Vieira CR; Aicher A; Real FX; Sainz B; Heeschen C
    Gastroenterology; 2014 Nov; 147(5):1119-33.e4. PubMed ID: 25127677
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KrasG12D-induced IKK2/β/NF-κB activation by IL-1α and p62 feedforward loops is required for development of pancreatic ductal adenocarcinoma.
    Ling J; Kang Y; Zhao R; Xia Q; Lee DF; Chang Z; Li J; Peng B; Fleming JB; Wang H; Liu J; Lemischka IR; Hung MC; Chiao PJ
    Cancer Cell; 2012 Jan; 21(1):105-20. PubMed ID: 22264792
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Mutant
    Perets R; Greenberg O; Shentzer T; Semenisty V; Epelbaum R; Bick T; Sarji S; Ben-Izhak O; Sabo E; Hershkovitz D
    Oncologist; 2018 May; 23(5):566-572. PubMed ID: 29371474
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Concurrent inhibition of pBADS99 synergistically improves MEK inhibitor efficacy in KRAS
    Tan YQ; Sun B; Zhang X; Zhang S; Guo H; Basappa B; Zhu T; Sethi G; Lobie PE; Pandey V
    Cell Death Dis; 2024 Feb; 15(2):173. PubMed ID: 38409090
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Catabolic pathways regulated by mTORC1 are pivotal for survival and growth of cancer cells expressing mutant Ras.
    Sung S; Choi J; Cheong H
    Oncotarget; 2015 Dec; 6(38):40405-17. PubMed ID: 26575954
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Endoscopic ultrasound-guided fine-needle aspirate-derived preclinical pancreatic cancer models reveal panitumumab sensitivity in KRAS wild-type tumors.
    Berry W; Algar E; Kumar B; Desmond C; Swan M; Jenkins BJ; Croagh D
    Int J Cancer; 2017 May; 140(10):2331-2343. PubMed ID: 28198009
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Aspartate β-hydroxylase promotes pancreatic ductal adenocarcinoma metastasis through activation of SRC signaling pathway.
    Ogawa K; Lin Q; Li L; Bai X; Chen X; Chen H; Kong R; Wang Y; Zhu H; He F; Xu Q; Liu L; Li M; Zhang S; Nagaoka K; Carlson R; Safran H; Charpentier K; Sun B; Wands J; Dong X
    J Hematol Oncol; 2019 Dec; 12(1):144. PubMed ID: 31888763
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Loss of Heterozygosity for
    Ma Y; Ling S; Li Y; Hu M; Kong B; Huang P; Liu H
    Int J Mol Sci; 2022 Jun; 23(12):. PubMed ID: 35743139
    [TBL] [Abstract][Full Text] [Related]  

  • 39. KRAS: feeding pancreatic cancer proliferation.
    Bryant KL; Mancias JD; Kimmelman AC; Der CJ
    Trends Biochem Sci; 2014 Feb; 39(2):91-100. PubMed ID: 24388967
    [TBL] [Abstract][Full Text] [Related]  

  • 40. KRAS Mutation Variants and Co-occurring PI3K Pathway Alterations Impact Survival for Patients with Pancreatic Ductal Adenocarcinomas.
    Diehl AC; Hannan LM; Zhen DB; Coveler AL; King G; Cohen SA; Harris WP; Shankaran V; Wong KM; Green S; Ng N; Pillarisetty VG; Sham JG; Park JO; Reddi D; Konnick EQ; Pritchard CC; Baker K; Redman M; Chiorean EG
    Oncologist; 2022 Dec; 27(12):1025-1033. PubMed ID: 36124727
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 23.